Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minnelide and Osimertinib in EGFR Mutated NSCLC
NCT05166616Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Mar 2022
- Primary completion
- Oct 2027
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of minnelide in non-small cell lung cancer (NSCLC), sponsored by City of Hope. Primary endpoints: Maximum Tolerated Dose up to 28 days and Recommended Phase II Dose up to 28 days. Started Mar 2022; status: active, not recruiting.
02
Drugs
minnelide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05166616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05166616.